BIOMAT Database Logo BIOMAT Database Logo

Combination therapy consisting of arterial infusion chemotherapy (EPF, EAP) and transcatheter arterial embolization (TAE). 1994

H Yodono, and S D Takekawa, and K Tarusawa, and I Ikami, and J Kanehira, and Y Saito, and S Takahashi, and T Sasaki, and N Nishi, and T Kimura
Department of Radiology, Hirosaki University Hospital, Japan.

From January 1988 to January 1993, 45 patients with unresectable advanced hepatocellular carcinoma (HCC) were treated with a new combination therapy consisting of arterial infusion chemotherapy and TAE. The combination therapy was performed according to our treatment schedule as follows: two courses of arterial infusion chemotherapy were given first, and then transcatheter arterial embolization (TAE) using a mixture of Lipiodol and cisplatin powder was performed. Two arterial infusion chemotherapeutic regimens were employed: EPF (etoposide, cisplatin, and 5-fluorouracil) and EAP (etoposide, Adriamycin or Epi-adriamycin, and cisplatin). The anticancer drugs were infused through a catheter inserted into the proper or common hepatic artery. Assessment was made of the anticancer effect and survival rate of each treatment method. The response to each therapy was evaluated on the basis of CT performed prior to and after the treatment. In the EPF.TAE group, the response rate was about 46%, whereas in the EAP.TAE group it was 48%. Overall, 21 of 45 patients attained a regression rate of 50% or more. Furthermore, daughter nodules decreased in size or disappeared in about 67% of 15 patients. Additionally, tumor thrombi tended to show a similar response. In all of the cases, the average duration of survival was 30.3 months, and the 1-year survival value was 68%, the 2-year survival value was 44%, and the 3-year survival value was 35%. These results were superior to those obtained with TAE therapy alone.

UI MeSH Term Description Entries
D007261 Infusions, Intra-Arterial Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease. Infusions, Regional Arterial,Infusions, Intra Arterial,Infusions, Intraarterial,Arterial Infusion, Intra,Arterial Infusion, Regional,Arterial Infusions, Intra,Arterial Infusions, Regional,Infusion, Intra Arterial,Infusion, Intra-Arterial,Infusion, Intraarterial,Infusion, Regional Arterial,Intra Arterial Infusion,Intra Arterial Infusions,Intra-Arterial Infusion,Intra-Arterial Infusions,Intraarterial Infusion,Intraarterial Infusions,Regional Arterial Infusion,Regional Arterial Infusions
D007459 Iodized Oil A preparation of oil that contains covalently bound IODINE. It is commonly used as a RADIOCONTRAST AGENT and as a suspension medium for CHEMOTHERAPEUTIC AGENTS. Oil, Iodized,Iodized Oils,Iodolipol,Oils, Iodized
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females

Related Publications

H Yodono, and S D Takekawa, and K Tarusawa, and I Ikami, and J Kanehira, and Y Saito, and S Takahashi, and T Sasaki, and N Nishi, and T Kimura
[Combination of transcatheter arterial infusion of SMANCS and embolization (SMANCS-TAE) for hepatocellular carcinoma].
February 1998, Gan to kagaku ryoho. Cancer & chemotherapy,
H Yodono, and S D Takekawa, and K Tarusawa, and I Ikami, and J Kanehira, and Y Saito, and S Takahashi, and T Sasaki, and N Nishi, and T Kimura
[Hepatic arterial infusion chemotherapy (HAI) for advanced hepatocellular carcinoma inefficacious with transcatheter arterial embolization (TAE)].
May 1998, Gan to kagaku ryoho. Cancer & chemotherapy,
H Yodono, and S D Takekawa, and K Tarusawa, and I Ikami, and J Kanehira, and Y Saito, and S Takahashi, and T Sasaki, and N Nishi, and T Kimura
[Bile lake: a complication of transcatheter hepatic arterial infusion and embolization therapy (TAI, TAE)].
February 1991, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica,
H Yodono, and S D Takekawa, and K Tarusawa, and I Ikami, and J Kanehira, and Y Saito, and S Takahashi, and T Sasaki, and N Nishi, and T Kimura
[Combination of transcatheter arterial infusion of SMANCS and embolization (SMANCS-TAE) for hepatocellular carcinoma--second report].
May 1998, Gan to kagaku ryoho. Cancer & chemotherapy,
H Yodono, and S D Takekawa, and K Tarusawa, and I Ikami, and J Kanehira, and Y Saito, and S Takahashi, and T Sasaki, and N Nishi, and T Kimura
Clinicopathological study on combination therapy consisting of arterial infusion of lipiodol-dissolved SMANCS and transcatheter arterial embolization for hepatocellular carcinoma.
January 1992, Cancer chemotherapy and pharmacology,
H Yodono, and S D Takekawa, and K Tarusawa, and I Ikami, and J Kanehira, and Y Saito, and S Takahashi, and T Sasaki, and N Nishi, and T Kimura
[One-shot therapy and transcatheter arterial embolization (TAE) therapy of unresectable hepatocellular carcinoma].
October 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
H Yodono, and S D Takekawa, and K Tarusawa, and I Ikami, and J Kanehira, and Y Saito, and S Takahashi, and T Sasaki, and N Nishi, and T Kimura
Transcatheter Arterial Embolization (TAE) of Cancer-Related Bleeding.
July 2023, Medicina (Kaunas, Lithuania),
H Yodono, and S D Takekawa, and K Tarusawa, and I Ikami, and J Kanehira, and Y Saito, and S Takahashi, and T Sasaki, and N Nishi, and T Kimura
[Transarterial "pile-up" infusion therapy of cisplatin and lipiodol emulsion in hepatic malignancies without TAE (transcatheter arterial embolization)].
March 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
H Yodono, and S D Takekawa, and K Tarusawa, and I Ikami, and J Kanehira, and Y Saito, and S Takahashi, and T Sasaki, and N Nishi, and T Kimura
[Transcatheter arterial embolization (TAE) therapy on a patient with polycystic kidney disease].
January 2012, Nihon Jinzo Gakkai shi,
H Yodono, and S D Takekawa, and K Tarusawa, and I Ikami, and J Kanehira, and Y Saito, and S Takahashi, and T Sasaki, and N Nishi, and T Kimura
[Hepatectomy after transcatheter arterial embolization (TAE) for hepatocellular carcinomas].
May 1985, Nihon Geka Gakkai zasshi,
Copied contents to your clipboard!